Cargando…

The Vivitrol pilot program (VPP): initial quantitative findings from an extended-release naltrexone study

Detalles Bibliográficos
Autores principales:	Rieckmann, Traci, Garvey, Katherine T, Srikanth, Priya, Andrich, Laura, Gregg, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4347562/ http://dx.doi.org/10.1186/1940-0640-10-S1-A54

Ejemplares similares

Whose mu fared better? The effect of extended-release naltrexone (XR-NTX) on treatment outcomes for opioid and alcohol users
por: Crèvecoeur-MacPhail, Desirée A
Publicado: (2015)

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

Lattice QCD calculation using VPP500
por: Kim, S, et al.
Publicado: (1994)

Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence
por: Wang, A-L, et al.
Publicado: (2015)

Key Factor Study for Generic Long-Acting PLGA Microspheres Based on a Reverse Engineering of Vivitrol(®)
por: Hua, Yabing, et al.
Publicado: (2021)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
por: Velasquez, Melissa, et al.
Publicado: (2019)

Pardon our dust: remodeling care to serve you better
por: McCarty, Dennis, et al.
Publicado: (2015)

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations
por: Cook, R. R., et al.
Publicado: (2023)

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
por: Nunes, Edward V., et al.
Publicado: (2015)

Factors associated with willingness to take extended release naltrexone among injection drug users
por: Ahamad, Keith, et al.
Publicado: (2015)

Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study
por: Marciuch, Anne, et al.
Publicado: (2022)

Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018
por: Jain, Priya, et al.
Publicado: (2020)

Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes
por: Hong, K., et al.
Publicado: (2016)

Medication Treatment for Opioid Use Disorders:: A Brief Overview with Comments on Extended Release Naltrexone
por: Woody, George
Publicado: (2017)

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
por: Marciuch, Anne, et al.
Publicado: (2023)

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results.
por: Selby, P., et al.
Publicado: (1990)

Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients
por: Zaaijer, Eline R., et al.
Publicado: (2015)

Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
por: Earley, Paul H., et al.
Publicado: (2017)

Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic
por: Nguyen, Thuy, et al.
Publicado: (2022)

The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
por: Parchinski, Kaley, et al.
Publicado: (2023)

AntiVPP 1.0: A portable tool for prediction of antiviral peptides
por: Beltrán Lissabet, Jorge Félix, et al.
Publicado: (2019)

Effects of milk-derived bioactive peptide VPP on diarrhea of pre-weaning calves
por: Zong, Xiaomei, et al.
Publicado: (2023)

Use of Naltrexone in Internet Gaming Disorder
por: Gour, Rahul, et al.
Publicado: (2022)

Epidemiologic and Molecular Pathophysiology of Chronic Opioid Dependence and the Place of Naltrexone Extended-Release Formulations in its Clinical Management
por: Reece, Albert Stuart
Publicado: (2012)

Adaptation of a standard extended-release naltrexone (XR-NTX) protocol for rural re-entering offenders with OUD
por: Staton, Michele, et al.
Publicado: (2021)

Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone
por: Karlsson, Ann Tarja, et al.
Publicado: (2022)

Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence
por: Li, Xinyi, et al.
Publicado: (2023)

Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma
por: Cocorocchio, E, et al.
Publicado: (2010)

Treatment of bipolar mania with paliperidone extended-release
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis
por: Hoffman, Kim A., et al.
Publicado: (2021)

Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.
por: Dady, P. J., et al.
Publicado: (1982)

Mind Perception: Real but Not Artificial Faces Sustain Neural Activity beyond the N170/VPP
por: Wheatley, Thalia, et al.
Publicado: (2011)

High levels of retinal docosahexaenoic acid do not protect photoreceptor degeneration in VPP transgenic mice
por: Li, Feng, et al.
Publicado: (2010)

Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012)

Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Caixàs, Assumpta, et al.
Publicado: (2014)

Maize ZmVPP5 is a truncated Vacuole H(+)‐PPase that confers hypersensitivity to salt stress
por: Sun, Xiaoliang, et al.
Publicado: (2016)

Co-Expression of ZmVPP1 with ZmNAC111 Confers Robust Drought Resistance in Maize
por: Liu, Shengxue, et al.
Publicado: (2022)

EHMTI-0087. Use of oxicodone/naloxone extended release for menstrual migraine
por: Mostardini, C, et al.
Publicado: (2014)

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
por: Kunøe, Nikolaj, et al.
Publicado: (2016)

The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature
por: Ramsey, Susan E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7esfprfm1vqh7e1p0tpmgj3vea